A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
GENTIAN DIAGNOSTICS ASA operates in the Medical - Devices industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 14M | 14M | 13M | 11M | 9.7M | 6.8M |
| Net Income | 4.2M | 4.2M | -1.0M | - | -2.9M | -1.9M |
| EPS | $0.27 | $0.27 | $-0.07 | $-0.16 | $-0.19 | $-0.12 |
| Free Cash Flow | 1.1M | 1.1M | 1.4M | -2.4M | -3.3M | -1.6M |
| ROIC | 32.5% | 13.3% | -12.4% | -21.7% | -28.6% | -25.4% |
| Gross Margin | 54.5% | 54.5% | 47.5% | - | - | - |
| Debt/Equity | 0.00 | 0.03 | 0.06 | 0.08 | 0.08 | 0.09 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.5M | 1.5M | -1.2M | -2.4M | -2.7M | -1.9M |
| Operating Margin | 10.3% | 10.3% | -9.4% | -22.9% | -27.5% | -28.1% |
| ROE | 23.3% | 26.4% | -6.7% | - | -14.0% | -9.0% |
| Shares Outstanding | 15M | 15M | 15M | - | 15M | 15M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.8M | 9.7M | 11M | 13M | 14M | 14M |
| Gross Margin | N/A | N/A | N/A | 47.5% | 54.5% | 54.5% |
| R&D | N/A | N/A | N/A | -3.4M | -2.1M | -2.1M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -1.9M | -2.7M | -2.4M | -1.2M | 1.5M | 1.5M |
| Op. Margin | -28.1% | -27.5% | -22.9% | -9.4% | 10.3% | 10.3% |
| Net Income | -1.9M | -2.9M | N/A | -1.0M | 4.2M | 4.2M |
| Net Margin | -27.6% | -29.8% | N/A | -7.9% | 29.8% | 29.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -25.4% | -28.6% | -21.7% | -12.4% | 13.3% | 32.5% |
| ROE | -9.0% | -14.0% | N/A | -6.7% | 26.4% | 23.3% |
| ROA | -7.4% | -11.6% | N/A | -5.5% | 21.9% | 19.7% |
| Cash Flow | ||||||
| Op. Cash Flow | -1.3M | -3.1M | -1.5M | 1.5M | 1.3M | 1.3M |
| Free Cash Flow | -1.6M | -3.3M | -2.4M | 1.4M | 1.1M | 1.1M |
| Owner Earnings | -2.4M | -4.5M | -2.9M | 271K | 180K | 180K |
| CapEx | 292K | 119K | 904K | 91K | 129K | 129K |
| Maint. CapEx | 708K | 856K | 1.1M | 908K | 839K | 839K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 708K | 856K | 1.1M | 908K | 839K | 839K |
| CapEx/OCF | N/A | N/A | N/A | 6.2% | 10.2% | 10.2% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 350K | 539K | 351K | 288K | 241K | 241K |
| Debt Repayment | 264K | 430K | 453K | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -15M | -12M | -7.3M | -7.5M | -7.4M | -7.9M |
| Cash & Equiv. | 17M | 13M | 8.5M | 8.3M | 7.9M | 7.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.09 | 0.08 | 0.08 | 0.06 | 0.03 | 0.00 |
| Interest Coverage | -12.0 | -5.7 | -5.5 | -3.7 | 6.2 | 6.2 |
| Equity | 21M | 20M | 16M | 14M | 18M | 18M |
| Total Assets | 25M | 25M | 20M | 17M | 22M | 22M |
| Total Liabilities | 4.3M | 4.3M | 3.5M | 3.3M | 3.3M | 3.3M |
| Intangibles | N/A | N/A | N/A | 2.0M | 2.7M | 2.7M |
| Retained Earnings | -11M | -15M | -16M | -16M | -11M | -11M |
| Working Capital | 18M | 17M | 12M | 11M | 12M | 12M |
| Current Assets | 21M | 19M | 15M | 13M | 15M | 15M |
| Current Liabilities | 2.4M | 2.6M | 2.3M | 2.4M | 2.8M | 2.8M |
| Per Share Data | ||||||
| EPS | -0.12 | -0.19 | -0.16 | -0.07 | 0.27 | 0.27 |
| Owner EPS | -0.15 | -0.30 | N/A | 0.02 | 0.01 | 0.01 |
| Book Value | 1.34 | 1.32 | N/A | 0.90 | 1.18 | 1.18 |
| Cash Flow/Share | -0.09 | -0.20 | N/A | 0.10 | 0.08 | 0.33 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 15.5M | 15.4M | N/A | 15.4M | 15.4M | 15.4M |
| Valuation | ||||||
| P/E Ratio | -53.4 | -43.0 | -26.5 | -62.3 | 12.8 | 157.8 |
| P/FCF | N/A | N/A | N/A | 45.7 | 46.9 | 577.6 |
| EV/EBIT | N/A | N/A | N/A | N/A | 31.0 | 438.4 |
| Price/Book | 4.8 | 6.1 | N/A | 4.5 | 2.9 | 36.0 |
| Price/Sales | 14.7 | 12.8 | N/A | 4.9 | 3.7 | 45.9 |
| FCF Yield | -1.6% | -2.6% | N/A | 2.2% | 2.1% | 0.2% |
| Market Cap | 100M | 124M | 0 | 63M | 53M | 653M |
| Avg. Price | 6.26 | 7.48 | 4.88 | 4.04 | 4.06 | 42.40 |
| Year-End Price | 6.45 | 8.07 | 4.25 | 4.08 | 3.44 | 42.40 |
GENTIAN DIAGNOSTICS ASA passes 3 of 9 quality checks, indicating weak fundamentals.
GENTIAN DIAGNOSTICS ASA trades at 157.8x trailing earnings, compared to its 15-year median P/E of 12.8x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 577.7x vs a median of 46.3x. The company's 5-year average gross margin is 51.0%. At current prices, the estimated annualized return to fair value is +26.8%.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a current P/E ratio of 157.8, compared to its historical median P/E of 12.8. The stock is currently considered Expensive based on its historical valuation range.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a 5-year average return on invested capital (ROIC) of -15.0%. This is below average and may indicate limited pricing power.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a market capitalization of $653M. It is classified as a small-cap stock.
GENTIAN DIAGNOSTICS ASA (GENT-OL) does not currently pay a regular dividend.
Based on historical P/E analysis, GENTIAN DIAGNOSTICS ASA (GENT-OL) appears expensive. The current P/E of 157.8 is 1131% above its historical median of 12.8. The estimated fair value CAGR (P/E method) is 82.5%.
GENTIAN DIAGNOSTICS ASA (GENT-OL) operates in the Medical - Devices industry, within the Healthcare sector.
GENTIAN DIAGNOSTICS ASA (GENT-OL) reported annual revenue of $14 million in its most recent fiscal year, based on SEC EDGAR filings.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a net profit margin of 29.8%. This is a strong margin indicating high profitability.
GENTIAN DIAGNOSTICS ASA (GENT-OL) generated $1 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
GENTIAN DIAGNOSTICS ASA (GENT-OL) reported earnings per share (EPS) of $0.27 in its most recent fiscal year.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a return on equity (ROE) of 26.4%. This indicates the company generates strong returns for shareholders.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a 5-year average gross margin of 51.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for GENTIAN DIAGNOSTICS ASA (GENT-OL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
GENTIAN DIAGNOSTICS ASA (GENT-OL) has a book value per share of $1.18, based on its most recent annual SEC filing.
No recent press releases.